Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Open accessThe DOI matches its Crossref record; 41 of the 51 references it cites were found in a registry or an index.
Abstract
Significance: Glucagon-like peptide-1 receptor agonists have become established as a leading class of diabetes medications. However, these peptide-based drugs are administered by subcutaneous injection or, in one case, by a complex oral dosing regimen. We now report the discovery of LY3502970, a potent and selective small-molecule GLP-1R agonist. LY3502970 exhibits preclinical pharmacology equivalent to a marketed injectable GLP-1R agonist and possesses pharmacokinetic properties compatible with oral dosing in humans. Cryoelectron microscopy (cryo-EM) studies reveal an ECD-driven receptor binding mode for LY3502970 that provides a favorable pharmacological profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2. Trp33ECD mediates key interaction with LY3502970 and the surrounding region. (A) Amino acid sequence comparison of the ECD regions for GLP-1Rs of different species. (B) LY3502970 increases cAMP accumulation in HEK293 cells expressing a chimeric form of the mouse GLP-1R (domains shown in green) where the N-terminal 142 residues have been replaced by the corresponding region of the human GLP-1R (domains shown in blue). (C) Mutation of Ser33ECD to Trp33ECD in the mouse GLP-1R enables LY3502970 to stimulate receptor-induced cAMP accumulation, while the reciprocal mutation (D) in the human GLP-1R abolishes compound function. The chimera and mutant data are presented as the mean ± SD of three independent experiments. (E) Trp33ECD interacts with LY3502970 and residues on TM2, ECL1, and ECL2. Residues and ligands are shown by sticks except Trp33ECD, which is also shown by spheres. Hydrogen bonds are indicated by dashed lines. (F) GLP-1R ECD orientation in the LY3502970 bound structure stabilized by aromatic interactions with ECL1. (G) The unique ECD orientation of ECD in the LY3502970 bound structure as a result of the unique Trp33ECD position. The structures of GLP-1R bound to LY3502970 (7TM in green, ECD in blue green, LY3502970 in magenta), GLP-1 (yellow, PDB ID code 6VCB), and peptide 5 (gray, PDB ID code 5NX2) are aligned. Trp33ECD is shown by a stick. Other peptide bound GLP-1R structures (GLP-1, PDB ID code 5VAI; ExP5, PDB ID code 6B3J) are not shown here, but their ECD orientations are very similar to GLP-1 bound structure 6VCB in yellow. (H and I) Competitive inhibition of [125I]GLP-1(7-36) binding to membranes isolated from cells expressing the human GLP-1R (H) or human W33S GLP-1R (I). Data are represented as the mean ± SD of three independent experiments.](https://figures.cochat.ai/paper-figures/acc41917547f432fb9ba49113ec198cd/structural-basis-for-glp-1-receptor-activation-by-ly3502970-an-orally-active-figure-2.jpg)


![Fig. 5. LY3502970 enhances glucose-stimulated insulin secretion and reduces food consumption in cynomolgus monkeys. (B–E) Effects of LY3502970 in IVGTT experiments. (A) Schematic diagram of the IVGTT procedure in anesthetized cynomolgus monkeys. Dosing of LY3502970 or exenatide was performed by manual bolus injection, followed by continuous infusion for 80 min. Forty minutes after initiating dosing of vehicle or the drug, glucose was administered intravenously. (B and C) Effect of LY3502970 (B) or exenatide (C) on blood glucose levels. (D and E) Effect of LY3502970 (D) or exenatide (E) on serum insulin levels. Data are represented as the mean ± SEM (n = 7). Significantly different from vehicle 1 or vehicle 2 by Dunnett’s test at *P < 0.025 and **P < 0.005 (one tailed), respectively. Vehicle 1: PEG400/PG/Gly NaOH buffer (pH 9), vehicle 2: 0.05% Tween80 PBS. (F and G) Mean food consumption following administration of LY3502970 (F) or exenatide (G). Cynomolgus monkeys were administered LY3502970, exenatide, or vehicle once daily for 5 d with a 2 d recovery period using an 8 × 5 cross-over design. Food consumption during the 90 min period after feeding was measured. Data are represented as the mean ± SEM (n = 8). Significantly different from the vehicle group by Dunnett’s test at **P < 0.005 (one tailed). Vehicle: dimethyl sulfoxide (DMSO)/Cremophor/PEG400/Gly-NaOH buffer (pH 10) [p.o.] + 0.05% Tween80 PBS [s.c.], LY3502970: LY3502970 [p.o.] + 0.05% Tween 80 PBS [s.c.], exenatide: DMSO/Cremophor/PEG400/Gly-NaOH buffer (pH 10) [p.o.] + exenatide [s.c.].](https://figures.cochat.ai/paper-figures/a9b9ab625235418ca4ecc2d8317f67c4/structural-basis-for-glp-1-receptor-activation-by-ly3502970-an-orally-active-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“More specifically, orforglipron is a potent partial GLP-1 RA which is biased towards G-protein activation over to β-arrestin recruitment at the GLP-1 receptor [23].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, orforglipron demonstrated a terminal half-life of 29-49 h in a phase 1b study in people with T2D, which allows once-daily oral dosing [25,28].”
From Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a previous report, treatment with orforglipron was found to promote glucose-dependent insulin secretion after a glucose challenge [25].”
From Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Orforglipron is an orally administered, non-peptide GLP-1 receptor agonist that can be taken once daily. However, it binds differently to the GLP-1 receptor compared to native GLP-1, thereby inducing G-protein activation rather than beta-arrestin recruitment [107].”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [107]
Experimental — accuracy not yet measuredIn the citing paper
“As a small molecule, orforglipron is chemically stable in the acidic gastric environment and is not a substrate for proteolytic enzymes such as dipeptidyl peptidase-4, enabling efficient absorption from the gastrointestinal tract after oral administration and eliminating the need for absorption enhancers or complex formulation strategies that are required for oral peptide GLP-1 therapies [33,34,35”
From Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes (2026) · cites this paper as [33]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716 · cited 1×
“This starting model was then subjected to iterative rounds of manual and Real Space Refinement in Coot (47, 48) and Phenix (49), respectively.”
MethodGuide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy
Zheng, S. Q., Palovcak, E., Armache, J.-P., Verba, K. A., Cheng, Y., & Agard, D. A. (2017) · Nature Methods · doi:10.1038/nmeth.4193 · Cited by 7,777 · cited 2×
“S. Q. Zheng et al., MotionCor2: Anisotropic correction of beam-induced motion for improved cryo-electron microscopy.”
MethodPHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
New tools for automated high-resolution cryo-EM structure determination in RELION-3
Zivanov, J., Nakane, T., Forsberg, B. O., Kimanius, D., Hagen, W. J., Lindahl, E., & Scheres, S. H. (2018) · eLife · doi:10.7554/elife.42166 · Cited by 4,621 · cited 1×
“Bayesian polishing and CTF refinement (46) were applied to further improve the map, resulting in a 3.”
MethodMolProbity: More and better reference data for improved all‐atom structure validation
Williams, C. J., Headd, J. J., Moriarty, N. W., Prisant, M. G., Videau, L. L., Deis, L. N., Verma, V., Keedy, D. A., Hintze, B. J., Chen, V. B., et al. (2018) · Protein Science · doi:10.1002/pro.3330 · Cited by 4,599 · cited 1×
“The final model was visually inspected for general fit to the map, and geometry was further evaluated using Molprobity (50).”
MethodGctf: Real-time CTF determination and correction
Zhang, K. (2016) · Journal of Structural Biology · doi:10.1016/j.jsb.2015.11.003 · Cited by 3,537
Guide for the Care and Use of Laboratory Animals: Eighth Edition -- Tamil Version
Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research, Studies, D. O. E. A. L., & National Research Council (2011) · National Academies Press eBooks · doi:10.17226/25801 · Cited by 1,118
Research works printed but not linked: 1
- Nguyen T., Drug structures displayed for the first time in Orlando. Chem. Eng. News (2019).
Cited by
Items 201–231 of 231
Mohammad, A., DASHTI, M. H., Malik, M. Z., Rajan, R., & Al‐Mulla, F. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.153525
Clinical Application and Research Progress of Novel Anti-Obesity Medications
商, 博. (2026) · Pharmacy Information · doi:10.12677/pi.2026.154043
Brubaker, J., Kim, S.-K., Li, B., Yang, M. Y., & Goddard, W. A. (2026) · Medicinal Chemistry Research · doi:10.1007/s00044-026-03579-6 · Cited by 1
“This is not a surprise, given the widespread notion that W33 ECD plays a critical role in small molecule binding to GLP-1R [6, 8, 12, 21, 23, 26].”
InfluentialOrforglipron alleviates aortic aneurysm and dissection via inhibiting WNT5A noncanonical signaling
Deng, Y., Zr, G., Yu, L., Zhang, J. W., Qian, J., Wang, J., Chen, X., Xu, Z., Wang, D., & Kong, C. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118294
Potential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist
Ramadurgum, P., Shah, J., Shah, E., & PALMER, B. F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1917800
“Cryo-electron microscopy shows that it occupies a distinct pocket in the upper helical bundle, formed by the extracellular domain, extracellular loop 2, and transmembrane helices 1, 2, 3, and 7, and stabilizes the active conformation without using the peptide-binding groove (Kawai et al., 2020).”
Oral Agents Used to Treat Type 2 Diabetes and Obesity
Liddle, J., Ratkova, E. L., Bonito, C. A., Rhodes, C. J., & Will, S. (2026) · Wiley eBooks · doi:10.1002/9783527845408.ch5
The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity
Roskoski, R. J. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108365 · Cited by 1
Lee, J., Son, S., Yoo, J. Y., Lee, J. H., Chun, M., & Park, S. B. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.4236524
Lee, J., Son, S., Yoo, J. Y., Lee, J. H., Chun, M., & Park, S. B. (2026) · Angewandte Chemie · doi:10.1002/ange.4236524
Oral small-molecule GLP-1 receptor agonists: a new Frontier in cardiometabolic medicine
Guo, J., & Chen, H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1933018
“It is a partial agonist at the human GLP-1 receptor (EC50 ~2 nM for cAMP) with > 1,000-fold selectivity over related class B GPCRs (Kawai et al., 2020).”
The promise of biased ligands in therapeutics
Eiger, D. S., Smith, J. S., & Rajagopal, S. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100160
Adedayo, L. D., Michael, O. S., Ayilara, G. O., Olumoroti, M. E., Bamidele, O., Samaila, S., Dhaya, I., Akorede, N. D., Abolarin, P. O., & Ofodile, L. N. (2026) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2026.1803200
ADVANCES IN OBESITY PHARMACOTHERAPY: CURRENT STATE AND FUTURE PERSPECTIVES
Wielogórska, A., Stasiak, O., Kowalik, F., & Deczkowska, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.5972
Hu, J., Zhang, Y., Wang, M., Zhang, B., Zhang, B., Ke, C., Tang, C., Xia, J., Zhao, Q., Gao, H., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00175
Structural Overview of GLP-1 Analogs
van der Velden, W. J. C., Andresen, A. F., & ROSENKILDE, M. M. (2026) · Biomedical Journal · doi:10.1016/j.bj.2026.101037
ReverseScreen.ai: Pharmacophore-Guided Reverse Screening Across the Growing Co-Complex ProteomePreprint
Muskal, S. M., & Nicola, G. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.09.750461 · Cited by 2
Peptidomimetics in GPCRs: From structural insights to clinical blockbusters
Li, G., Zhou, Q., & Wang, M. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.09.010 · Cited by 1
Hegaz, M. G., Aboud, M. Y. A., Kamel, A. I. I., Naveed, M. A., Elsayad, O. G., & Sorathia, A. Z. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02538-x
“…agonist that favors the activation of G protein more than β-arrestin, with the potential of a similar physiological outcome to the first-line drugs and offers a high bioavailability without the necessity of food and water restriction, favoring it over other injectable GLP-1 agonists [11, 12].”
Tamrakar, S., Pe, L. S., Panmanee, J., Yang, J., & Mukda, S. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119946
Orforglipron: An Oral GLP-1 Receptor Agonist for Obesity Treatment
Wietholter, J. P., & Terpening, C. M. (2026) · Annals of Pharmacotherapy · doi:10.1177/10600280261486055
Nguyễn, M. C., Le, M.-T., & Tran, H. N. K. (2026) · RSC Advances · doi:10.1039/d6ra06052h
Badrealam, K. F., Alameri, R. M., Raouf, Y. S., Maurel, D., Wani, N. A., Shmygol, A., Anwar, I., See, H. B., Johnstone, E. K. M., Dupuis, E., et al. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70677
Progress in Anti-Obesity Drug Development: A Pharmacodynamics Perspective
Ahmad, I., Azmi, S., Albabtain, M. A., Mustafa, M., Kunnathodi, F., Riyasdeen, A., AlWhaiby, B. R., Alharbi, E. M., Arafat, A. A., & Alotaibi, H. F. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18101281
“…helices 1, 2, 3 and 7, and its activity depends on the primate-specific residue Trp33 of the extracellular domain; rodents carry serine at this position and do not respond, so wild-type rodent efficacy data do not translate for this class and humanized or Glp1r S33W models are required [78,115].”
PROTFIG: one-command, publication-quality biomolecular figuresPreprint
Chi, L. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.20.760606
“Using the orforglipron-bound GLP-1R structure [11], PROTFIG generates six distinct representations from the same input, highlighting the binding site, molecular interactions, electrostatic properties, and overall architecture (Fig.”
BindingDB Entry 50022117: Binding sites and design strategies for small molecule GLP-1R agonists.
BindingDB (2025) · UC San Diego · doi:10.7270/q2474gk6
BindingDB (2023) · UC San Diego · doi:10.7270/q2736w0v
Seo, Y., & Woo, J. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104843
Metadata
- Authors
- Kawai, T., Sun, B., Yoshino, H., Feng, D., Suzuki, Y., Fukazawa, M., Nagao, S., Wainscott, D. B., Showalter, A. D., Droz, B. A., Kobilka, T. S., Coghlan, M. P., Willard, F. S., Kawabe, Y., Kobilka, B. K., & Sloop, K. W.
- Affiliations
- Chugai Pharmaceutical Co., Ltd. (Japan) (JP)
- ConfometRx (United States) (US)
- Eli Lilly (United States) (US)
- Corresponding author
- Suzuki, Yoshiyuki
- Kobilka, Brian K.
- Sloop, Kyle W.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2020-11-11
- Volume
- 117
- Issue
- 47
- Pages
- 29959-29967
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC7703558
- OpenAlex
- W3099724881
- Cited by
- 231
- References
- 51
- Citations by year
- 2026: 68 · 2025: 53 · 2024: 44 · 2023: 30 · 2022: 19 · 2021: 15 · 2020: 2
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- GLP-1 receptor, class B G protein-coupled receptors, receptor structure, partial agonism, biased signaling, G protein activation, beta-arrestin, oral antidiabetic drugs, type 2 diabetes, insulin secretion, blood glucose reduction, non-human primates
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Protein Domains, Glucagon-Like Peptide-1 Receptor Agonists, Administration, Oral, Aminopyridines, Animals, Benzamides, Humans, Hypoglycemic Agents, Macaca fascicularis, Male, Mice, Transgenic, Models, Molecular, Species Specificity, Swine, Tryptophan, Mutagenesis, Site-Directed, Anti-Obesity Agents, Cryoelectron Microscopy, Mice, Rats, Incretins, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.